As the most common stem cell type being used within regenerative medicine, there is huge potential for growth within the mesenchymal stem cell (MSC) market. Today, MSCs are the most common stem cell type being used within clinical trials, as well as the most studied stem cell type within the scientific literature. [Read more…]
Propagenix – Interview with the President and CEO, Brian Pollok, Ph.D.
Propagenix is a preclinical-stage platform technology company that is applying its unique technology to both internal and partnered cell therapy programs. The company is engaged in the development and commercialization of technology which originated from the laboratory of Dr. Richard Schlegel of Georgetown University.
Of course, I am always interested in technologies transferred from Georgetown, because I attended the university for Graduate Studies in Biochemistry and Molecular Biology.
Headquartered in Rockville, Maryland, Progagenix was founded in 2014 by Brian Pollok, Ph.D. Pollok is the company’s Co-Founder, as well as its current President and CEO. I am honored to release this interview in which we discuss the company’s core technology, its preclinical-stage programs, and future goals. Enjoy.
denovoMATRIX Introduces Ready-to-use, Chemically Defined Coated Cell Cultureware for Serum-free hMSC Expansion
August 22, 2019, Dresden, Germany — Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells (hMSC) offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment. [Read more…]
Nucleus Biologics acquires Primorigen Biosciences, gains proprietary, high yield, recombinant protein platform
SAN DIEGO, Aug. 6, 2019 — Nucleus Biologics, a leader in precision cell culture, is pleased to announce the acquisition of Primorigen Biosciences, Inc. The addition of Primorigen’s Vitronectin XF™ and platform recombinant protein production technology will play a huge role in Nucleus’ strategy of offering traceable, reproducible and xeno-free (XF) cell culture ecosystems for the cell and gene therapy space. [Read more…]
GenCure announces breakthrough first run of 80-liter bioreactor
Biomanufacturing CDMO among first to harvest adult stem cells at large scale
SAN ANTONIO, Texas – In a breakthrough for the regenerative medicine industry, GenCure announced today that its biomanufacturing services team has successfully completed production runs expanding and harvesting human mesenchymal stem cells (hMSCs) in an 80-liter bioreactor. GenCure, a subsidiary of BioBridge Global (BBG), announced a major expansion of its biomanufacturing facilities in February of this year. [Read more…]
